Boston venture capital firm Third Rock Ventures is set to disclose Thursday that it is putting up $47 million to launch a cancer immunotherapy start-up in Cambridge.
The company will be called Jounce Therapeutics Inc., a name derived partly from a well-known physics term and partly from a synonym for jolt. It is meant to signal the dramatic change the company and its financial backers expect from their cancer-fighting approach.
Comments
This is great news! I'm very familliar with breast cancer detection via several methods the most interesting of which uses a radiotracer that's bound to a type of sugar. Cancer cells are hungry little devils which draw in glucose in order to support the growth of new blood vessels so they can feed themselves and grow ever faster. I wish Jounce the best in this new venture. My only advice is to remain a private or VC based company. Forget about going public since that has killed more innovative thought than it has launched. The market is unforgiving no matter how good your technology is.